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KETAMINE: A FEASIBLE REPLACEMENT 
FOR CURRENT MAJOR DEPRESSIVE DISORDER THERAPIES 
EGE DERMAN 
ABSTRACT 
     Major depressive disorder (MDD) is among the most common mental health 
problems in the U.S. and the world. A significant portion of patients with MDD do 
not respond to current antidepressant medications and are considered treatment-
resistant. Current antidepressant therapies have a late onset of action that causes 
significant challenges when treating patients with suicidal ideation. In the past two 
decades, there has been significant interest in the anesthetic drug ketamine as an 
antidepressant. Evidence suggests that ketamine is effective even in treatment-
resistant patients, with rapid onset of benefits observed hours after administration. 
The U.S. Food and Drug Administration has recently approved a nasal spray 
containing the S-enantiomer of ketamine, or esketamine, as an antidepressant 
therapy. This thesis reviewed the literature on both ketamine and esketamine as 
antidepressants, with a focus on the two most commonly used routes of 
administration, intravenous infusion and intranasal administration. This study 
concludes that both ketamine and esketamine have robust and rapid antidepressant 
effects. Both formulations are safe and well tolerated by patients, with transient, 
nonserious side effects easily managed and monitored by healthcare providers. 
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Further research should focus on broadening the availability of ketamine and 
esketamine to patients.   
 
 vi 
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Depression is among the most common mental health problems in the United 
States (U.S.) and the world. The World Health Organization estimates that the 
prevalence of depression globally is 4.4%, or 322 million people (World Health 
Organization, 2017). According to the Centers for Disease Control and Prevention, 
an estimated 16 million patients in the U.S. are affected by depression every year 
(Brody et al., 2018). Results from the nationwide Sequenced Treatment Alternatives 
to Relieve Depression (STAR*D) study show that only 30% of patients with major 
depressive disorder (MDD) achieved remission after their first antidepressant (AD) 
trial. At the end of the study in which participants could receive up to four different 
AD therapy options, 33% of patients did not achieve remission. In addition, the time 
to achieve remission across therapy steps was up to 5 to 7 weeks (Rush et al., 2006). 
These results point to two main problems encountered when treating MDD. The 
first problem is that a large number of MDD patients are treatment-resistant and do 
not respond to first-line antidepressants, indicating the need for treatment options 
with greater efficacy. The second problem is that antidepressants commonly used 
today take a long time to achieve their therapeutic effects.  
The delay in the onset of therapeutic benefits poses a significant problem in 
psychiatric medicine because people suffering from MDD have an increased risk of 
suicide. An extensive systematic review by Angst et al. (1999) found that among all 
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suicide autopsies, the rate of diagnosed MDD was 20% to 35%. An average of 15% 
of all MDD patients treated in inpatient settings died by suicide, and the mortality 
rates of people with mood disorders were higher by 40% to 150% compared with 
the general population (Angst et al., 1999). In addition, the initiation of a new 
selective serotonin reuptake inhibitor (SSRI), a commonly prescribed class of 
antidepressants, was linked to an increase in suicidal risk in the first two weeks 
after its introduction. Data from the STAR*D study showed that 4.2% of participants 
who reported no suicidal ideation (SI) at baseline reported new SI, and 8.7% of 
participants who had SI at baseline reported worsening SI. The majority of 
emergent or worsening SI reports were in the first two weeks of treatment 
(Coughlin et al., 2016). The high risk of suicide in MDD patients, combined with the 
increased risk of SI in the first two weeks of antidepressant therapy, highlights the 
need for more rapid-acting antidepressant treatments.  
 In the last two decades, ketamine has emerged as a novel antidepressant 
treatment that is a rapid-acting drug with promising results in treatment-resistant 
depression (TRD). Ketamine has been used as a short-acting anesthetic drug since 
the 1970s (Hashimoto, 2019). In the early 2000s, research began to indicate 
ketamine as a potent and fast-acting antidepressant with remarkably high efficacy. 
Because ketamine is a long-standing and generic drug, pharmaceutical companies 
lack the financial incentive to conduct the clinical trials necessary to get U.S. Food 
and Drug Administration (FDA) approval for this new indication. However, 
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prescribers around the world use ketamine for the off-label indication of depression 
in refractory cases. As of 2018, an estimated 300 clinics in the U.S. offered ketamine 
therapies for depression in an array of formulations, including intravenous (IV) 
infusions, intramuscular (IM) injections, subcutaneous injections, and oral tablets 
(Hashimoto, 2019). 
 The increase in research on the antidepressant effects of ketamine led to the 
approval of the drug Spravato, (Janssen Pharmaceuticals, 2020) generic name 
esketamine, in 2019 by the FDA. Esketamine contains the S-enantiomer of ketamine, 
and it is administered intranasally. The initial approval was for use in conjunction 
with an oral antidepressant for treatment-resistant depression. A year later, the FDA 
approved the additional indication for use in MDD with SI or behavior in 
conjunction with an oral antidepressant (Janssen Pharmeceuticals, 2020). 
The goal of this literature review is to provide an overview of the 
antidepressant effects of ketamine and its enantiomers.  
 
Major Depressive Disorder and Antidepressants 
Diagnosis criteria for major depressive disorder currently used in the U.S. 
have been established by the Diagnostic and Statistical Manual of Mental Disorders, 
5th Edition (DSM-5). Symptoms include depressed mood, anhedonia, changes in 
sleep, changes in appetite, difficulty focusing or thinking, SI, psychomotor 
retardation or agitation, fatigue, and feelings of worthlessness or excessive guilt. To 
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meet diagnostic criteria, five or more of these symptoms must be present in a 2-
week period with either depressed mood or anhedonia. The yearly prevalence of 
MDD in the U.S. population is approximately 7% (American Psychiatric Association, 
2013). 
Currently, the most commonly prescribed class of antidepressants to treat 
MDD is the selective serotonin reuptake inhibitors (SSRIs). An analysis of all insured 
patients in the U.S who had a new diagnosis of MDD and were initiated on a new 
antidepressant between 2003 and 2014, showed that 73.5% of those prescriptions 
were SSRIs (Keyloun et al., 2017). SSRIs inhibit the reuptake of the neurotransmitter 
serotonin from the synapse by blocking the serotonin transporter (SERT). The 
initial inhibition of the transporters causes an increase of serotonin levels in the 
brain, preferentially at the midbrain raphe, which contains the soma of serotonergic 
neurons. Serotonin autoreceptors are located at the soma and regulate the serotonin 
release from the axon terminals of these neurons. The increase in serotonin levels 
stimulates the serotonin autoreceptors, inhibiting additional serotonin release from 
the neurons. Over time, the increased stimulation causes the autoreceptors to 
downregulate and become desensitized. This desensitization leads to a disinhibition 
of the serotonergic neuron and an increase in serotonin levels because serotonin 
can no longer regulate its own release with the autoreceptors. This mechanism of 
action corresponds to the time course of SSRI effects. The initial increase in 
serotonin and the stimulation of the autoreceptors correspond to the side effects 
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seen in the first few weeks after initiation of an SSRI. The downregulation of 
autoreceptors and the increase in signaling of the serotonergic neurons correspond 
to the antidepressant effects seen later in the treatment (Stahl, 2013). As of 2019, 
seven SSRIs are approved by the FDA to treat MDD: citalopram, escitalopram, 
paroxetine, fluoxetine, vortioxetine, vilazodone, and sertraline (Office of the 
Commissioner, 2020). During the STAR*D study, citalopram was used as the first AD 
treatment with a 47% overall response rate (defined as 50% or greater decrease on 
the Quick Inventory of Depressive Symptomology–Self-Report [QIDS-SR] scores). Of 
those patients who responded to citalopram, 56% achieved response at or after 2 
months of treatment, highlighting the delay in onset of therapeutic effects 
associated with SSRIs (Trivedi et al., 2006). 
Another commonly used drug class is the serotonin-norepinephrine reuptake 
inhibitors (SNRIs). These drugs inhibit both the SERT and norepinephrine 
transporters. Because norepinephrine transporters are also responsible for the 
majority of dopamine clearance in the prefrontal cortex, the inhibition causes an 
increase in dopamine signaling in addition to the serotonin and norepinephrine 
signaling (Stahl, 2013). The FDA-approved SNRIs include duloxetine, venlafaxine, 
levomilnacipran, and desvenlafaxine (Office of the Commissioner, 2020).  
Other atypical antidepressants commonly prescribed are norepinephrine-
dopamine reuptake inhibitors (bupropion), alpha-2 autoreceptor antagonists for 
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norepinephrine (mirtazapine), and serotonin antagonist/reuptake inhibitors 
(trazodone and nefazodone) (Stahl, 2013). 
The two other classical antidepressant classes are the tricyclic (or 
tetracyclic) antidepressants and the monoamine oxidase inhibitors (MAOIs). MAOIs 
were the first class of antidepressants that was discovered. They inhibit the enzyme 
monoamine oxidase A, which is responsible for the breakdown of major 
neurotransmitters, such as serotonin, norepinephrine, and dopamine, inside 
neurons. This inhibition causes an increase in serotonin and norepinephrine levels 
but has no effect on dopamine levels because monoamine oxidase-B can still 
metabolize dopamine. MAOIs are no longer utilized as first-line therapy for MDD on 
account of problems with common drug interactions and dietary restrictions which 
need to be followed while taking them. Both of these problems can lead to serious 
side effects, and patients on MAOIs need to be monitored closely (Stahl, 2013). 
MAOIs currently approved by the FDA to treat MDD are selegiline, isocarboxazid, 
phenelzine, and tranylcypromine (Office of the Commissioner, 2020).  
The second class of older antidepressant drugs is the tricyclic and tetracyclic 
antidepressants, named after their three- or four-ringed atomic structure. The 
majority of these antidepressants work by inhibiting serotonin and norepinephrine 
reuptake, but some have additional agonist actions on serotonin receptors. The 
main drawback of this class of drugs is that most of them can also block muscarinic 
acetylcholine receptors, histamine receptors, adrenaline receptors, or voltage-gated 
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sodium channels, and this capability leads to a wide variety of unwanted side effects 
(Stahl, 2013). Although still in use today, especially in patients that do not respond 
to the more commonly used antidepressants, they are not considered as first-line 
therapy because of the potential for serious side effects. Current tricyclic 
antidepressants approved by the FDA to treat MDD include amoxapine, 
amitriptyline, maprotiline, desipramine, nortriptyline, doxepin, trimipramine, and 
protriptyline (Office of the Commissioner, 2020). 
 
Treatment-Resistant Depression and Treatment Options 
 Defining treatment resistance is a major problem in the field, and no 
consistent definition for TRD currently exists (Gaynes et al., 2020). Most studies on 
the antidepressant effects of ketamine on TRD patients use the criteria of two or 
more failed antidepressant trials of adequate dose and duration. However, even 
within that definition, there are variations. Adequate duration is commonly defined 
as 4 or 6 weeks of AD treatment. Failure of an AD trial can be defined as failure to 
respond (defined by not achieving a decrease of at least 50% of scores on a 
depression scale) or failure to enter remission (defined by a drop below a 
determined score on depression scales) (Gaynes et al., 2020). Because of these 
problems in defining treatment-resistant depression, it is difficult to estimate 
prevalence. The STAR*D study found an overall remission rate of 67%. The 
remaining 33% of MDD patients in this study were treatment-resistant after four 
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treatment trials that included a variety of antidepressants, cognitive behavioral 
therapy, and other pharmaceutical augmentation strategies (Rush et al., 2006). 
 Three atypical antipsychotics (or second-generation antipsychotics) are FDA-
approved for use in conjunction with an SSRI or an SNRI for TRD: a D2 dopamine 
receptor partial agonist (aripiprazole), a dopamine and serotonin receptor 
antagonist (quetiapine), and a dopamine receptor partial agonist (brexpiprazole). 
Another atypical antipsychotic, olanzapine, is a dopamine and serotonin receptor 
antagonist approved by the FDA for TRD and used in combination with the SSRI 
fluoxetine (McIntyre et al., 2014; Stahl, 2013). Placebo-controlled studies have 
shown promising efficacy for these drugs in TRD. However, antipsychotics can have 
serious side effects requiring close monitoring throughout the treatment period. 
Studies of antipsychotics used in TRD often report high discontinuation rates due to 
significant weight gain, abnormal laboratory results, hormone imbalances, sedation, 
and akathisia (Spielmans et al., 2013; Wang et al., 2016). 
 Another treatment option with proven efficacy in TRD is neurostimulation, 
with procedures like electroconvulsive therapy (ECT), repeated transcranial 
magnetic stimulation (rTMS), and vagus nerve stimulation (VNS). ECT has been used 
in the U.S. since the 1930s. Treatments are usually administered 2 or 3 times a week 
under general anesthesia. ECT works by using electrodes placed on the skull to pass 
small currents through the brain, triggering brief seizures. How these seizures 
produce antidepressant effects is still not well understood. Since 1979, ECT has 
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been approved by the FDA for the treatment of depression and is used on 
treatment-resistant individuals who fail multiple antidepressant medication trials. 
ECT can also be used in acute cases of severe SI because it has rapid therapeutic 
benefits which emerge immediately after initial treatment. The efficacy of ECT is 
remarkably high with response rates reported at 50% to 60% in treatment-resistant 
patients. Although ECT is safe and well tolerated, there are well-known risks of 
cognitive deficits especially related to memory loss and acute confusion states after 
treatment. Concern for cognitive deficits has made both patients and caregivers 
reserve ECT for exceedingly treatment-resistant patients (Kellner et al., 2012; 
Kennedy et al., 2009). 
 Repeated transcranial magnetic stimulation involves creating a magnetic 
field by using coils placed on the patient’s head to produce electrical currents in the 
brain that affect neuronal function. Treatments are usually done 5 times a week. 
Unlike ECT, there are no seizures in the brain, and general anesthesia is not needed 
during the procedure. This procedure was approved by the FDA in 2008 for 
treatment-resistant depression. Because rTMS does not produce seizures, there is 
minimal risk for cognitive side effects, and it is well tolerated by patients. However, 
studies controlled with placebo treatments have reported a response rate of 25% in 
treatment-resistant patients, much lower than the high efficacy reported for ECT 
(Kennedy et al., 2009). 
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 Vagus nerve stimulation is a more invasive procedure involving the 
implantation of an electrode around the left vagus nerve, which is then stimulated 
with electrical signals. It is theorized that the stimulation activates brain areas 
important for depression and modulates monoaminergic neurotransmission, but 
the mechanism of action is not well understood. The FDA approved this procedure 
in 2005 for treatment-resistant depression. Overall, VNS is well tolerated with some 
acute side effects in the neck area from the surgical procedure. No cognitive decline 
has been observed. The major drawback of this neurostimulation technique is that 
patients need to go through an invasive surgical procedure. This reason is why VNS 
is only used in severely treatment-resistant MDD patients. Studies report a response 
rate similar to rTMS of 15% to 30% in TRD (Kennedy et al., 2009).  
 
Brief History of Ketamine 
Phencyclidine (PCP) was first synthesized in 1956 as a general anesthetic. 
Despite its good anesthetic properties, PCP caused severe side effects including 
hallucinations, delirium, and confusion in patients. This led to the termination of the 
use of PCP as a general anesthetic; however, a search ensued for a similar drug with 
similar anesthetic properties but a better side effect profile. In 1962, the 
pharmaceutical company Parke-Davis synthesized ketamine, and the first human 
trials of ketamine were conducted by Dr. Edward Domino and Dr. Guenter Corssen 
in 1964 (Wei et al., 2020). In a later review by Dr. Domino (2010), he provided the 
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first record of the antidepressant effects of ketamine and described interviewing 
PCP and ketamine abusers in the 1970s. These patients reported abusing these 
drugs for their rapid therapeutic effects when other antidepressants were not 
effective (Domino, 2010). After human trials, ketamine was approved by the FDA as 
an anesthetic and analgesic in 1970. Ketamine was used as an analgesic on 
American soldiers injured during the Vietnam War because its large margin of safety 
allowed it to be administered in the battlefield (Domino, 2010). Research by Sofia 
and Harakal in 1975 provided the first evidence for the antidepressant effects of 
ketamine on mice models (Sofia & Harakal, 1975). During the 1990s, other N-
methyl-D-aspartate (NMDA) receptor antagonists were found to have 
antidepressant actions in mice models, and these results increased the interest in 
ketamine as well. In 1994, Krystal et al. investigated the neurological, cognitive, and 
behavioral effects of IV ketamine infusions in subanesthetic doses on healthy 
subjects and documented the anxiolytic effects of ketamine (Krystal et al., 1994). 
This led to the wide interest in ketamine as an antidepressant in the 2000s. 
 
Pharmacokinetics of Ketamine 
Ketamine is a rapid-acting drug with a short half-life of 3 hours in humans 
(Duman et al., 2012). Ketamine or its S-enantiomer, esketamine, is cleared in the 
liver by cytochrome P450 enzymes through N-demethylation that produces 
noresketamine (Perez-Ruixo et al., 2020). Ketamine is both water- and lipid-soluble, 
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making it available for multiple routes of administration (Schüttler & Schwilden, 
2008). The oral bioavailability of ketamine is exceedingly low with an estimated 
18.6% absolute bioavailability from the extensive first-pass metabolism in the liver. 
Oral administration is also slow with a mean absorption time of 2.02 hours. For 
intranasal administration, researchers found that for a 25-mg dose, 54% of 
ketamine was absorbed through the nasal cavity, whereas the remaining 46% was 
swallowed and followed oral absorption parameters. As the intranasal dose 
increased to 56, 84, and 112 mg, the percentage of drug absorbed through the nasal 
cavity decreased to 44%, 40%, and 38%, respectively. The researchers postulated 
that this decrease in intranasal absorption was due to the vasoconstrictive effect of 
ketamine on the blood vessels of the nasal cavity. Therefore, the absolute 
bioavailability for an intranasal dose of 28 to 112 mg of ketamine ranges from 63% 
to 50% (Perez-Ruixo et al., 2020). 
 
Stereoselectivity of Ketamine 
Ketamine is a racemic mixture made up of equal parts of its S- and R-
enantiomers. Spravato, the intranasal spray approved by the FDA, contains only the 
S-enantiomer. The S-enantiomer has a 4 times greater affinity for the NMDA 
receptor compared with the R-enantiomer. This greater affinity of esketamine 
produces a 3 to 4 times greater anesthetic potency and greater psychotomimetic 
side effects (Zhang et al., 2014). 
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Researchers have found that the R-enantiomer of ketamine has longer-
lasting antidepressant effects in depression models of mice (Zhang et al., 2014). In 
addition, R-ketamine has shown a greater antidepressant efficacy and less drug-
seeking behaviors or dependence in rats. (Yang et al., 2015). Research on healthy 
human volunteers also found a significantly greater number of side effects reported 
after IV infusions of S-ketamine compared with R-ketamine, consistent with mouse 
models. Besides common side effects, no significant difference between the 
enantiomers was found on cognitive testing (Persson et al., 2002). However, 
evidence comparing the antidepressant effects of these ketamine enantiomers is 
lacking.  
 
Mechanism of Action of Ketamine 
Ketamine acts as a noncompetitive antagonist at N-methyl-D-aspartate 
(NMDA)-type glutamate receptors. Glutamate is a major excitatory 
neurotransmitter in the mammalian brain. NMDA glutamate receptors are ligand-
gated ion channels permeable to K+, Ca2+, and Na+ ions in their open state. Ketamine 
blocks the NMDA receptors by binding to the PCP binding site located within the ion 
channel (Schüttler & Schwilden, 2008). Blocking the NMDA receptors, which are 




There are two main proposed hypotheses on the mechanism of action of 
ketamine. The first is the disinhibition hypothesis, which posits that low doses of 
ketamine act on cortical inhibitory interneurons as an antagonist. Under basal 
conditions, the NMDA receptors on these inhibitory neurons are tonically activated 
and continuously inhibit the excitatory pyramidal neurons (PNs). Ketamine 
interrupts this continuous activation by blocking the NMDA receptors. This results 
in the indirect activation of excitatory PNs, producing an overall excitatory effect 
(Miller et al., 2016). The second hypothesis is the direct hypothesis in which 
ketamine acts directly on PNs and disrupts the basal activation through NMDA 
receptors. This triggers a compensatory mechanism of excitatory input from other 
neurons that increases and produces an overall excitation of the PNs (Miller et al., 
2016). 
The antidepressant effects of ketamine are also modulated by the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Blocking 
this receptor with an AMPA receptor antagonist, 2,3-dihydroxy-6-nitro-7-
sulfoamoylbenzo(f)-quinozaline (NBQX), significantly lowers the antidepressant 
effects of ketamine in mice (Maeng et al., 2008). In contrast, pretreatment with 
NBQX does not alter the antidepressant effects of traditional monoamine-acting 
antidepressants (Zanos & Gould, 2018).  
Activation of AMPA receptors leads to the release of a signaling protein, 
brain-derived neurotrophic factor (BDNF) (Duman et al., 2012). Ketamine 
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administration rapidly increases BDNF levels in the rat hippocampus, whereas 
traditional antidepressants, like fluoxetine, do not alter BDNF levels (Garcia et al., 
2008). BDNF signaling appears to be a crucial step for the mechanism of action of 
ketamine. Knockout mice that lack the BDNF gene show no antidepressant benefits 
after ketamine administration (Zanos & Gould, 2018). 
The release of BDNF causes the activation of the mammalian target of 
rapamycin (mTOR) signaling pathway. The mTOR signaling pathway leads to the 
synthesis of proteins required for synaptogenesis. Li et al. (2010) found that 
subanesthetic doses of ketamine cause rapid and transient activation by 
phosphorylation of several signaling proteins in the pathway in the prefrontal 
cortex of mice. Local infusion of rapamycin, which blocks mTOR signaling, results in 
a complete absence of antidepressant effects. Other antidepressant therapeutics, 
including electroconvulsive therapy, fluoxetine (SSRI), and imipramine (tricyclic 
antidepressant), do not significantly affect mTOR signaling, suggesting a unique 
mechanism of action for ketamine (Li et al., 2010). Interestingly, the induction of 
mTOR signaling is only observed at subanesthetic doses of ketamine, an effect that 
follows a U-shaped curve and disappears at higher anesthetic doses (Duman et al., 
2012).  
The activation of mTOR signaling increases protein synthesis and results in 
the formation of new synapses. Researchers have observed increased spine density 
of prefrontal cortex pyramidal neurons after ketamine injections. The increase in 
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synapses causes a general increase in serotonin levels in the brain, which is 
commonly associated with widely used antidepressant medications (Li et al., 2010). 
In addition to inducing synaptogenesis, ketamine administration is also associated 
with the formation of more mature neuronal spines by increasing spine stability and 
function, 24 hours after exposure. Mice models exposed to chronic stress show 
reduced spine density and lower amplitude of excitatory postsynaptic potentials 
(EPSPs) in cortical neurons. After a single ketamine infusion, researchers have 
observed a complete reversal of spine density and EPSP deficits, suggesting an 
important mechanism for antidepressant effects (Duman et al., 2012). 
Ketamine also acts on opioid receptors in the brain that have been associated 
with its antidepressant actions. Before IV ketamine infusion, Williams et al. (2018) 
administered TRD patients with either placebo or an opioid receptor antagonist, 
naltrexone, which would eliminate any effects of ketamine on opioid receptors. The 
results showed that patients who received placebo before ketamine infusion had a 
significantly greater reduction of depression symptoms, as measured by the 
Hamilton Depression Rating Scale (HDRS), compared with those who received 
naltrexone. On Day 1 postinfusion, 7 of 12 patients on placebo and none of the 
patients on naltrexone met response criteria (Williams et al., 2018). These findings 
suggest that the actions of ketamine on opioid receptors may be integral in its 
antidepressant effects and need to be considered with the more widely accepted 






This section reviews 16 studies on the antidepressant effects of IV ketamine and 

















Single IV Ketamine Infusion 
  Berman et al. (2000) conducted the first placebo-controlled ketamine 
infusion study on patients with MDD. Seven patients with a current major 
depressive episode underwent two infusions, separated by a week, in a crossover 
design of placebo saline and ketamine (0.5 mg/kg over 40 minutes). Starting at 230 
minutes after initiating infusions, IV ketamine produced a statistically significant 
decrease in HDRS scores compared with the decrease observed after placebo. Fifty 
percent of patients met response criteria (50% or greater decrease in HDRS scores) 
within 3 days after ketamine infusions. HDRS scores returned to baseline (5 points 
within baseline HDRS scores) 1 to 2 weeks after the last infusion. This small but 
seminal study showed the potential of ketamine as an antidepressant, both with its 
remarkable efficacy and its rapid action. More important, the researchers noted the 
downside of using saline as placebo, especially in a crossover study design. Because 
patients receive both placebo and ketamine, participants can potentially 
differentiate between placebo and the “high” feeling of ketamine. Unblinding can 
mitigate placebo effects and alter the accuracy of the efficacy results (Berman et al., 
2000). 
 Zarate et al. (2006) published another randomized, placebo-controlled study 
comparing a single IV ketamine infusion (0.5mg/kg over 40 minutes) with placebo 
saline in 18 patients with treatment-resistant MDD (recurrent depressive episode 
and a minimum of 2 failed AD trials). This study employed a similar crossover 
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design as Berman et al. (2000). Results showed a statistically significant decrease in 
mean HDRS scores after ketamine infusion compared with placebo. The decrease in 
depressive symptoms started at 110 minutes postinfusion and lasted through the 7-
day observation period. One day after ketamine treatment, 71% of participants met 
response criteria (≥50% reduction in HDRS scores) and 21% met remission criteria 
(HDRS scores ≤ 7) (Zarate et al., 2006). The response rate of 71% is exceedingly 
high, given the treatment-resistant study population. Like the study by Berman et al. 
(2000), Zarate et al. (2006) used saline for placebo and acknowledged the 
possibility that unblinding might have contributed to the high efficacy rates in their 
study. 
Machado-Vieira et al. (2009) administered a single IV ketamine infusion 
(0.5mg/kg over 40 minutes) to 23 treatment-resistant MDD patients in an open-
label study and measured plasma levels of BDNF. As previously mentioned, evidence 
from studies on rats has shown that BDNF levels increase in the brain after 
ketamine infusion, and BDNF signaling appears to be crucial for its antidepressant 
effects (Garcia et al., 2008; Zanos & Gould, 2018). At 230 minutes after ketamine 
infusion, results showed a statistically significant decrease in Montgomery-Asberg 
Depression Rating Scale (MADRS) scores compared with baseline, consistent with 
findings from placebo-controlled studies by Berman et al. (2000) and Zarate et al. 
(2006). However, there was no statistically significant increase in plasma BDNF 
levels after the infusion. The researchers concluded that BDNF signaling does not 
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appear to be mediating the rapid antidepressant effects of ketamine in humans but 
instead might be important in later sustained effects of the drug (Machado-Vieira et 
al., 2009).  
An open-label study by Ibrahim et al. (2011) compared antidepressant 
effects of IV ketamine (0.5mg/kg over 40 minutes) on treatment-resistant MDD 
patients (2 or more failed AD trials) who had failed ECT treatment (n = 17; failed to 
respond to 6 bilateral or 7 unilateral ECT sessions) with those who were never 
treated with ECT (n = 25). At 230 minutes after infusion, the mean MADRS scores of 
both groups were significantly lower compared with baseline. There were no 
statistically significant differences in the number of responders (50% decrease in 
MADRS scores) between groups. The researchers concluded that the ECT-resistant 
group had a similar response to ketamine as the ECT-naive group (Ibrahim et al., 
2011). As discussed previously, ECT treatment is considered highly effective and is 
reserved for the extremely treatment-resistant MDD population that has failed 
multiple antidepressant trials. ECT-resistant patients included in this study by 
Ibrahim et al. (2011) had an average length of illness of 26 years, highlighting the 
severity of their treatment resistance. Results of this small study suggest that 
ketamine is just as effective in the extremely treatment-resistant population and 
might provide a long-awaited relief for these patients. 
A randomized control trial by Murrough, Iosifescu, et al. (2013) compared 
the antidepressant effects of an active placebo control, midazolam, with an IV 
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ketamine infusion (0.5 mg/kg over 40 minutes) on 72 treatment-resistant MDD 
patients (failed to achieve response to at least 3 AD medications; currently 
experiencing a recurrent depressive episode or chronic depressive episode of at 
least 2 years’ duration). Previous studies by Berman et al. (2000) and Zarate et al. 
(2006) had used saline as a placebo, which can cause unblinding of participants 
from the recognizable “high” feeling of ketamine infusion. Midazolam is an 
anesthetic benzodiazepine that produces similar sedation or disorientation effects 
as ketamine; therefore, it can prevent unblinding when used as a placebo. At 24 
hours after the infusion, patients receiving ketamine had a statistically significant 
reduction in MADRS scores compared with the reduction due to placebo. There was 
a statistically significant difference between the response rates of the ketamine and 
placebo arms. The response rate (≥50% improvement in MADRS scores) for the 
ketamine group was 64% compared with 28% for the placebo group. At the follow-
up phase, a steady increase in depressive symptoms was observed in both treatment 
groups, and by Day 7 postinfusion, there was no statistically significant difference 
between groups in mean MADRS scores (Murrough, Iosifescu, et al., 2013). Even 
with the more stringent treatment-resistant criteria of 3 failed AD trials and the use 
of an active placebo control, the response rate from this larger study was similar to 
previous placebo-controlled studies by Berman et al. (2000) and Zarate et al. 
(2006). Data from these three placebo-controlled studies of a single IV ketamine 
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infusion (0.5 mg/kg over 40 minutes) show that ketamine has a response rate 
ranging from 50% to 71% in treatment-resistant MDD patients. 
Hu et al. (2016) conducted a placebo-controlled study on a group of 30 
patients presenting with active SI. Study participants consisted of 55.7% with 
treatment-resistant MDD (2 or more failed AD trials) and the rest with MDD. 
Different from all other previously mentioned IV ketamine trials, this study initiated 
an oral antidepressant, escitalopram (10 mg/day), for all participants concurrently 
with a single infusion of placebo saline or IV ketamine (0.5 mg/kg over 40 minutes). 
Afterward, patients continued antidepressant treatment for 4 weeks without any 
additional infusions. Ketamine was associated with a greater reduction in MADRS 
scores compared with placebo. A statistically significant difference between groups 
was observed starting at 2 hours and lasting until 2 weeks after infusion. The 
researchers concluded that at the 2-week point, patients started experiencing 
therapeutic benefits from the oral antidepressant, resulting in the disappearance of 
the difference between groups. At 4 weeks, the overall response rate (50% or 
greater reduction in MADRS scores) was 92.3% for the ketamine arm compared 
with 55.6% for the placebo arm. For treatment-resistant patients, the response rate 
was 88.9% in the ketamine group compared with 33.3% in the placebo group. In 
addition, the mean time for patients to achieve response was 6.4 days for the 
ketamine arm compared with 26.5 days for the placebo arm (Hu et al., 2016). The 
large difference in the onset of therapeutic benefits makes ketamine an extremely 
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attractive therapy option for all MDD patients and not just the treatment-resistant 
population. The high response rates in the ketamine arm show the remarkable 
efficacy that ketamine infusions can have in MDD, regardless of treatment 
resistance, when used concurrently with oral antidepressants. The significant 
difference between MADRS scores of ketamine and placebo groups disappeared 
after 2 weeks in this study. The researchers concluded that this was due to the 
increase in antidepressant actions of escitalopram instead of a loss of 
antidepressant effects of ketamine. The increase in AD actions of escitalopram may 
have allowed the placebo group to catch up to the ketamine group as the MADRS 
scores of both groups remained low for the 4-week study period (Hu et al., 2016). 
A study by Fava et al. (2020) compared antidepressant effects of an active 
placebo (midazolam) with different doses of ketamine infusions (0.1, 0.2, 0.5, or 1 
mg/kg over 40 minutes) on treatment-resistant MDD patients (2 or more failed AD 
trials). Participants were allowed to continue taking stable doses of psychoactive 
medications. The researchers found that 24 hours after infusion, only the 0.5 and 1 
mg/kg ketamine doses produced a statistically significant reduction in HDRS scores 
compared with placebo. The antidepressant effects began to diminish starting at 3 
days after treatment (Fava et al., 2020). Considering the majority of IV ketamine 
infusions administered to treat depression are given in a dose of 0.5 mg/kg over 40 
minutes, the results from Fava et al. (2020) appear to support this dose as the 




Multiple IV Ketamine Infusions 
Aan het Rot et al. (2010) recruited 10 patients with treatment-resistant 
depression who had previously responded to ketamine infusions and had 
experienced relapse afterward. Participants received 3 infusions a week for 2 weeks 
for a total of 6 infusions (0.5 mg/kg over 40 minutes). One participant did not meet 
response criteria (≥50% reduction in MADRS scores) after the first infusion and 
was removed according to protocol. At 2 weeks, all remaining participants who 
received 6 doses met response criteria, and 8 participants met remission criteria 
(MADRS scores ≤ 9). During the follow-up phase, the average time until relapse 
after the last dose was 19 days for 8 patients, and 1 patient remained in remission 
for more than 3 months (aan het Rot et al., 2010). The preliminary results from this 
study suggest that response to ketamine infusions can be sustained safely with 
repeated infusions similar to long-term oral antidepressant use. 
Murrough, Perez, et al. (2013) conducted an open-label study on 24 
treatment-resistant MDD patients (2 or more failed AD trials). Participants received 
6 infusions in an identical schedule to the multiple-infusion study by aan het Rot et 
al. (2010). Two hours after the first infusion, all participants experienced a 
statistically significant decrease in MADRS scores compared with baseline. The 
overall response rate (≥50% improvement in MADRS scores) at the end of the study 
was 70%. In the follow-up period, the median time until relapse was 18 days after 
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the last infusion. Patients who met response criteria after the first infusion 
sustained response for all remaining infusions, and mean MADRS scores continued 
to show a small but significant decrease. These findings strengthen the results from 
aan het Rot et al. (2010) that repeated ketamine infusions can sustain initial 
response. In contrast, nonresponders had an initial significant decrease in mean 
MADRS scores, but they tended to have a small increase in depressive symptoms 
over subsequent infusions. This result suggests that for nonresponders, repeated 
doses of ketamine might not lead to response or to additional antidepressant 
benefits (Murrough, Perez, et al., 2013). 
Cusin et al. (2017) completed an open-label study on 12 treatment-resistant 
MDD patients (3 or more failed AD trials) with current SI lasting 3 months or more. 
The researchers investigated the antidepressant effects of an increasing dose 
regimen of IV ketamine. Participants were allowed to continue antidepressant 
medications and received 2 ketamine infusions a week for 3 weeks. The first 3 
infusions were given at the standard subanesthetic dose of 0.5mg/kg over 45 
minutes, and the subsequent infusions were given at a higher dose of 0.75 mg/kg 
over 45 minutes. At the end of 3 weeks, 41.5% of participants met response criteria 
(≥50% decrease in HDRS scores). There was a statistically significant reduction in 
HDRS scores after the sixth infusion when compared with scores at baseline and 
after the first infusion. In addition, there was a statistically significant difference 
between the decrease in HDRS scores after higher dose infusions compared with the 
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decrease after the standard dose. This result shows that HDRS scores continued to 
improve throughout the 6 infusions with greater benefits observed after the higher 
doses. However, the researchers noted that it is difficult to differentiate the 
increased efficacy of the higher dose from the cumulative effects of repeated 
ketamine doses. Four out of 5 responders relapsed within 2 weeks after the last 
infusion (Cusin et al., 2017). The previous open-label study by Murrough, Perez, et 
al. (2013), with 6 ketamine infusions dosed at 0.5 mg/kg and treatment resistance 
defined as 2 failed AD trials, had reported a response rate of 70%. Results from 
Cusin et al. (2017) may represent the efficacy of ketamine infusions in a more 
treatment-resistant sample, particularly because of the inclusion criteria of 3 failed 
AD trials. Even after administering a higher ketamine dose of 0.75 mg/kg for the last 
3 infusions, response rates were much lower compared with Murrough, Perez, et al. 
(2013). 
Wilkinson et al. (2018) published results from a psychiatric hospital 
administering open-label ketamine infusions in both inpatient and outpatient 
settings. The clinic treated 54 treatment-resistant patients with a variety of mood 
disorders. Infusions of IV ketamine (0.5 mg/kg over 40 minutes) were administered 
on a variable schedule of either once a week or twice a week. Compared with 
baseline, results showed a statistically significant decrease in depressive symptoms 
measured by QIDS-SR or MADRS scores. The response rate (≥50% improvement in 
QIDS-SR scores) was 45.5% after 4 infusions. A subgroup of 14 participants received 
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long-term ketamine infusions with a mean treatment duration of 75.7 weeks. 
Previous studies had established that repeated infusions can sustain the 
antidepressant effects in the short term (aan het Rot et al., 2010; Murrough, Perez, 
et al., 2013). Preliminary results from this subsample indicate that for patients 
experiencing relapse after short-term treatment, repeated ketamine infusions can 
be used to maintain long-term response (Wilkinson et al., 2018). 
 
IV Ketamine Infusions for Suicidal Ideation 
Price et al. (2009) investigated the effects of ketamine on suicidal ideation in 
26 treatment-resistant MDD patients (2 or more failed AD trials). Participants 
received a single infusion of IV ketamine (0.5 mg/kg over 40 minutes). At 24 hours 
after infusion, 62% of participants who had significant SI at baseline (Montgomery-
Asberg Depression Rating Scale suicidality item [MADRS-SI] scores ≥ 4) achieved 
scores of 0 or 1, corresponding to no SI or minimal SI (Price et al., 2009). These 
preliminary results suggest that IV ketamine can be used to rapidly resolve 
significant SI. Unfortunately, the results are not generalizable to the population of 
MDD patients with SI, as patients with severe, active SI were excluded from the 
study because of safety concerns. 
An open-label study done by DiazGranados et al. (2010) consisted of 33 
treatment-resistant MDD patients regardless of SI severity. Participants received a 
single IV ketamine infusion (0.5mg/kg over 40 minutes). At 40 minutes after 
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infusion, there was a statistically significant decrease from baseline in mean scores 
on three different scales measuring suicidal ideation: MADRS-SI, Scale for Suicidal 
Ideation (SSI), and Hamilton Depression Rating Scale suicide item (HDRS-SI). All 10 
participants who had reported significant levels of SI (SSI > 3) at baseline went 
below an SSI score of 4 within hours. At 24 hours, 6 out of 10 patients with higher SI 
achieved remission (score of 0 on the SSI) (DiazGranados et al., 2010). Unlike the 
preliminary study by Price et al. (2009) that excluded patients with significant 
suicidal ideation, DiazGranados et al. (2010) recruited treatment-resistant MDD 
patients regardless of SI severity. Therefore, results from this study are more 
generalizable to the MDD population. Despite the small sample size and the open-
label design, the treatment-resistant nature of the patients and the short duration of 
onset show the unprecedented potential of ketamine as a rapid-acting 
antidepressant treatment that can resolve significant SI in TRD patients in 
emergency settings. 
In the study by Murrough, Perez, et al. (2013) previously discussed with 
other multiple infusion studies, suicidal ideation improved for the entire study 
sample regardless of response status. The reduction in SI in the absence of response 
highlights the unique anti-SI effects of ketamine and suggests that ketamine might 
be used in emergency cases of SI regardless of its other antidepressant benefits 
(Murrough, Perez, et al., 2013). 
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 Murrough et al. (2015) published results from a randomized placebo-
controlled study that used midazolam as placebo. The researchers investigated 
antidepressant effects of a single IV ketamine infusion (0.5mg/kg over 40 minutes) 
on 24 patients with a variety of mood disorders, presenting with significant SI 
(MADRS-SI scores  4). A majority of patients had a diagnosis of MDD and were 
included in the study regardless of treatment-resistant status. Participants were 
allowed to continue taking other psychoactive medications during the study. One 
day after the infusion, there was a statistically significant decrease in mean MADRS-
SI scores for ketamine compared with placebo. Two days after the infusion, a 
statistically significant difference between groups also emerged in Beck Scale for 
Suicidal Ideation (BSI) scores. All statistically significant differences between groups 
disappeared 7 days after the infusion (Murrough et al., 2015). In a previous study, 
DiazGranados et al. (2010) had demonstrated anti-SI effects of ketamine on 
treatment-resistant MDD patients with significant SI in an open-label study. Results 
from Murrough et al. (2015) strengthen the evidence for the anti-SI effects of 
ketamine using an active placebo-controlled design. In addition, this study included 
MDD patients regardless of treatment resistance, and results suggest that all MDD 
patients can achieve relief from SI using ketamine infusions. 
In 2016, Ionescu et al. assessed the effects of ketamine on suicidal ideation 
from the study by Cusin et al. (2017). Twelve treatment-resistant MDD patients with 
current SI received 2 IV ketamine infusions a week over 3 weeks, with the first 3 
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dosed at 0.5 mg/kg and the last 3 dosed at 0.75 mg/kg. They found a statistically 
significant decrease in suicidal ideation measured by Columbia-Suicide Severity 
Rating Scale (C-SSRS) scores and HDRS-SI scores after 6 infusions compared with 
baseline. A decrease in C-SSRS scores was observed after each infusion. At the end 
study, 50% of patients met remission criteria for SI (score of 0 on C-SSRS) (Ionescu 
et al., 2016). This is the first study in this review that demonstrated anti-SI effects of 
ketamine on highly treatment-resistant MDD patients with active SI across multiple 
infusions. The results suggest that like antidepressant benefits, subsequent 
ketamine infusions can sustain and increase anti-SI benefits of ketamine. However, 
as already mentioned, it is difficult to differentiate the effects of multiple infusions 
from the effects of an increasing dose regimen. 
 Grunebaum et al. (2018) conducted a randomized, placebo-controlled clinical 
trial on 80 MDD patients, regardless of treatment resistance, with significant SI (SSI 
scores  4). Participants received a single IV infusion of either racemic ketamine (0.5 
mg/kg over 40 minutes) or an active placebo control, midazolam. All patients were 
allowed to keep using their current psychoactive medications. One day after 
infusion, 55% of participants in the ketamine group met response criteria (50% or 
greater reduction in SSI scores), and there was a statistically significant decrease in 
the mean SSI scores of the ketamine group compared with placebo. The researchers 
found that the decrease in SI was generally maintained for the 6-week follow-up 
period (Grunebaum et al., 2018). This study had a similar design to a previous study 
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by Murrough et al. (2015) that had a smaller sample size and showed similar anti-SI 
efficacy of ketamine infusions. Results from Grunebaum et al. (2018) found that 
anti-SI effects of ketamine infusions were maintained for 6 weeks after a single 
infusion. This suggests that the anti-SI effects of ketamine infusions might last 
longer than antidepressant effects, which were reported as lasting from 1 to 2 
weeks after a single infusion (Berman et al., 2000; DiazGranados et al., 2010).  
 
IV Esketamine Infusions 
A study by Singh et al. (2016) investigated antidepressant effects of IV 
esketamine in 30 treatment-resistant MDD patients (2 failed AD trials). Participants 
were randomized to receive placebo (saline) or IV esketamine infusions of either 0.2 
mg/kg or 0.4 mg/kg over 40 minutes on Day 1. Because esketamine has a greater 
affinity for NMDA receptors, the dose of 0.4 mg/kg of esketamine was chosen as an 
equivalent dose to 0.5 mg/kg of ketamine. On Day 4, responders (50% reduction in 
MADRS scores) received a second dose of the same infusion. For nonresponders, 
those who had received placebo were randomized to receive 0.2 or 0.4 mg/kg 
esketamine, those who had received 0.2 mg/kg were increased to the 0.4 mg/kg 
dose, and those who received 0.4 mg/kg received the same dose for the second 
infusion. After the two double-blind treatments, 26 participants were enrolled in an 
open-label phase where they received up to 4 infusions of 0.3 mg/kg or 0.4 mg/kg 
esketamine based on tolerability. Twenty-four hours after the first infusion, there 
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was a statistically significant decrease in the mean MADRS scores of both 
esketamine groups compared with placebo. Response rates after the first treatment 
were 67% for 0.2 mg/kg esketamine and 64% for 0.4 mg/kg esketamine infusions, 
with no responders in the placebo group (Singh et al., 2016). This small study had 
similar response rates to previous IV ketamine studies. The study by Fava et al. 
(2020) had demonstrated that IV ketamine doses lower than 0.5 mg/kg did not 
produce significant antidepressant effects. In contrast, Singh et al. (2016) found 
significant antidepressant benefits with the lower dose of 0.2 mg/kg esketamine, 
suggesting a lower than equivalent dose can be used.  
 
Intranasal Studies 
This section reviews 8 studies on the antidepressant effects of intranasal 
ketamine and esketamine. Table 2 summarizes these studies in chronological order 
for the period 2014 to 2020.
 







 Lapidus et al. (2014) investigated the antidepressant effects of intranasal 
racemic ketamine (50 mg) in a randomized placebo-controlled (saline) study. The 
18 participants had a primary diagnosis of treatment-resistant MDD (1 or more 
failed AD trials). Patients were assigned to receive esketamine or placebo in a 
crossover design 7 days apart, and they were allowed to continue treatment on 
stable doses of current medications including antidepressants. Twenty-four hours 
after administration, intranasal ketamine produced a statistically significant 
reduction in MADRS and QIDS-SR scores over placebo. For 44% of participants, 
response criteria (50% reduction in MADRS scores) were met at 24 hours. At 7 days 
postinfusion, no significant difference between the two conditions could be 
detected. The researchers also collected blood samples to measure plasma ketamine 
levels. The mean ketamine plasma levels were 84 ng/mL at 40 minutes, much lower 
than the 200 ng/mL at 40 minutes measured after IV infusions (0.5 mg/kg for 40 
minutes) in previous studies (Lapidus et al., 2014). The lower plasma ketamine 
levels suggest that a higher than 50-mg dose might be needed for intranasal 
administration to achieve the same effects as IV infusions. Despite lower blood 
levels, the results show that intranasal ketamine can be an effective treatment as an 






 Results of a phase 2 intranasal esketamine study were published by Daly et 
al. (2018). For this study, 67 treatment-resistant MDD patients (2 or more failed AD 
trials) were recruited, and participants were allowed to continue stable doses of 
psychiatric medications. In the first phase of the study, participants were 
randomized into placebo (water with bittering agent) or 28, 56, or 84 mg 
esketamine administered twice intranasally over 1 week. The bittering agent is used 
in intranasal studies to mimic the bitter taste of esketamine and maintain blinding 
of participants. In the second phase of the study, participants in the placebo group 
who did not have an antidepressant response were randomized into the esketamine 
groups for twice weekly administration over 1 week. Afterward, 57 participants 
enrolled in the open-label phase of the study regardless of their previous response. 
Open-label participants received doses based on tolerability and efficacy, twice 
weekly for the first 2 weeks, weekly for the next 3 weeks, and once every 2 weeks 
thereafter. There was a statistically significant improvement in mean MADRS scores 
in all esketamine groups compared with placebo. The results also showed a 
correlation between higher ketamine doses and a greater decrease in MADRS 
scores. Response rates (50% decrease in MADRS scores) at the end of 2 weeks 
were 38%, 36%, and 50% for 28-, 56-, and 84-mg doses, respectively. During the 8-
week follow-up phase, participants sustained improvements in mean MADRS scores. 
The researchers found that the 56- and 84-mg intranasal esketamine 
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administrations produced similar plasma esketamine levels as an IV esketamine 
administration of 0.2 mg/kg, which was considered to produce similar clinical 
effects as an IV ketamine infusion of 0.5 mg/kg (Daly et al., 2018). Previously, Singh 
et al. (2016) had demonstrated that IV esketamine infusions of both 0.2mg/kg and 
0.4 mg/kg doses produced remission rates of 62%-64% in treatment-resistant 
patients. The Daly et al. (2018) study reported a similar response rate of 50% after 
an intranasal esketamine dose of 84mg, suggesting intranasal administration can be 
as effective as IV infusion. 
Results from a phase 3 study were published by Popova et al. (2019). The 
223 participants had treatment-resistant MDD (2 or more failed AD trials) without 
significant SI. Patients were started on a new oral antidepressant (duloxetine, 
escitalopram, sertraline, or venlafaxine extended release) and were randomized to 
receive esketamine or placebo (with bittering agent) twice a week for 4 weeks. All 
patients receiving esketamine were started on a 56-mg dose that could be increased 
to 84 mg based on efficacy and tolerability. At 4 weeks, the results showed a 
statistically significant improvement in MADRS scores in the esketamine arm 
compared with placebo. Response rates (≥50% decrease in MADRS scores) were 
69% in the esketamine arm and 52% in the placebo arm (Popova et al., 2019). The 
response rate of 69% from this study using intranasal esketamine in conjunction 
with an oral antidepressant is markedly higher than the previous study (Price et al., 
2018) that found a response rate of 36% to 50% with intranasal esketamine. This 
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higher response rate suggests that esketamine nasal spray used in conjunction with 
a newly initiated AD can yield greater antidepressant benefits than esketamine as a 
monotherapy.  
 Fedgchin et al. (2019) reported on the results of a phase 3 study on 346 
treatment-resistant MDD patients (2 or more failed AD trials). All participants were 
initiated on an oral antidepressant (duloxetine, escitalopram, sertraline, or 
venlafaxine extended release) at the beginning of the study and were randomized to 
placebo (with bittering agent) or 56 or 84 mg intranasal esketamine. 
Administrations were done twice weekly for 4 weeks. At the end of the treatment 
period, 54.1% of patients on 56 mg and 53.1% of patients on 84 mg esketamine 
achieved response (≥50% decrease in MADRS scores) compared with 38.9% of 
patients in the placebo group. The results showed no statistically significant 
difference in mean MADRS scores between the 84 mg, 56 mg, and the placebo 
groups. The higher-than-expected response rate of the antidepressant/placebo 
group compared with efficacy data from the STAR*D study may explain the lack of 
statistical significance between the ketamine and placebo groups. The same 
phenomenon was also reported in another phase 3 clinical trial previously 
mentioned by Popova et al. (2019). Although there was no statistically significant 
difference between groups, MADRS scores compared with baseline numerically 
favored esketamine arms over placebo at all time points (Fedgchin et al., 2019). 
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Daly et al. (2019) investigated sustaining response to intranasal esketamine 
in a phase 3 clinical trial. The study recruited 297 participants with a diagnosis of 
treatment-resistant MDD (2 or more failed AD trials) who had previously responded 
(≥50% decrease in MADRS scores) or achieved remission (MADRS scores  12) 
with esketamine treatment. All patients were stabilized on a new oral AD regimen 
(duloxetine, escitalopram, sertraline, or venlafaxine extended release). 
Concurrently, patients were randomized to receive either esketamine (56 or 84 mg 
based on previous tolerability and efficacy) or placebo (with bittering agent). The 
drug or placebo was administered on a flexible schedule of either once weekly or 
once every 2 weeks based on efficacy. In patients who achieved stable remission, 
26.7% receiving esketamine and 45.3% receiving placebo experienced relapse 
during the study. In patients who achieved stable response, 25.8% receiving 
esketamine and 57.6% receiving placebo experienced relapse during the study. 
Results showed that continued esketamine treatment produced a statistically 
significant reduction in relapse rates compared with placebo. A 70% decreased risk 
was found in patients with stable response, and a 50% decreased risk was found in 
patients in stable remission. In addition, esketamine treatment was associated with 
a statistically significant delay in the onset of relapse compared with placebo (Daly 
et al., 2019). Previous multiple IV ketamine infusion studies had shown that 
continued administrations could sustain antidepressant benefits in the short term 
using 6 infusions over 2 weeks (aan het Rot et al., 2010; Murrough, Perez, et al., 
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2013). Results from Daly et al. (2019) suggest a similar pattern of repeated 
intranasal esketamine administration that can sustain antidepressant effects and 
prevent relapse. 
An open-label, phase 3 study of intranasal esketamine by Wajs et al. (2020) 
assessed the efficacy and side effects of long-term use in 802 patients with 
treatment-resistant MDD (2 or more failed AD trials). During the first 4 weeks of the 
study, all participants were initiated or stabilized on an oral AD (duloxetine, 
escitalopram, sertraline, or venlafaxine extended release) and received esketamine 
2 times a week for 4 weeks. Esketamine dose was adjusted to either 24, 56, or 84 mg 
depending on tolerability of the drug. At Week 5, all responders (50% reduction in 
MADRS scores) continued oral AD therapy with current esketamine dose 
administered once a week or once every 2 weeks based on efficacy. The mean 
MADRS scores showed a statistically significant decrease from baseline during the 
first 4 weeks of treatment. Low MADRS scores were maintained for the majority of 
responders throughout the 1-year study period. Response rate at the end of the 
study was 76.5% (Wajs et al., 2020). These results suggest that intranasal 
esketamine is efficacious when used with long-term multiple administrations. A 
similar pattern was found in a previous study of long-term IV ketamine infusions 
that could sustain antidepressant response over a mean duration of 75 weeks 




Intranasal Esketamine for Suicidal Ideation 
Canuso et al. (2018) published the results of a proof-of-concept, phase 1 
study on the efficacy of intranasal esketamine (56 or 84 mg) in MDD patients with 
significant SI. All participants were initiated or stabilized on an oral antidepressant 
medication and randomized to esketamine or placebo (with a bittering agent). 
Participants received 2 doses of intranasal esketamine a week, and doses could be 
reduced to 56 mg from 84 mg for intolerance. At 24 hours after initial 
administration, the esketamine group had a statistically significant decrease in 
MADRS scores compared with placebo. In addition, 40% of participants who 
received esketamine had a resolution of suicidal ideation at 24 hours (clinician 
global judgment of suicide risk scores 0-1). No significant differences between 
groups were observed at the end of the 8-week follow-up period (Canuso et al., 
2018). These results suggest that intranasal esketamine can rapidly resolve suicidal 
ideation for patients with MDD and are consistent with previous findings on the 
anti-SI effects of IV ketamine infusions (Grunebaum et al., 2018). 
Fu et al. (2020) published results of a phase 3 intranasal esketamine trial on 
226 patients with a diagnosis of MDD who had active suicidal ideation with intent. 
After recruitment, all participants were stabilized on antidepressant therapy of 
either oral antidepressant monotherapy or antidepressant with augmentation (a 
second antidepressant, atypical antipsychotic, or mood stabilizer). Participants 
received either 84 mg of nasal esketamine or placebo (with bittering agent) twice a 
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week for 4 weeks. Dose adjustment to 56 mg was allowed based on tolerability. 
Patients receiving esketamine had a statistically significant reduction in mean 
MADRS scores compared with placebo, starting at 4 hours and lasting throughout 
the 4-week treatment period. Remission (MADRS scores ≤ 12) rates at the end of 
treatment were 54% for esketamine compared with 38% for placebo. Both study 
arms had a reduction in suicidal ideation compared with baseline (Suicide Ideation 
and Behavior Assessment Tool [SIBAT] scores), with no statistically significant 
difference between them. The researchers suggest that this was due to the beneficial 
impact of establishing a comprehensive standard of care through hospitalization, 
antidepressant treatment, and extensive clinical contact, all of which contributed to 
the placebo effect on suicidal symptoms more than depressive symptoms (Fu et al., 
2020). 
 
Onset and Duration 
Ketamine is a rapid-acting drug with a markedly faster onset of 
antidepressant benefits compared with other traditional antidepressants. For IV 
infusions of ketamine or esketamine, the onset of antidepressant effects is between 
40 and 240 minutes after treatment (aan het Rot et al., 2010; Berman et al., 2000; 
DiazGranados et al., 2010; Grunebaum et al., 2018; Ibrahim et al., 2011; Machado-
Vieira et al., 2009; Murrough, Perez, et al., 2013; Singh et al., 2016; Zarate et al., 
2006). The onset of therapeutic effects after intranasal ketamine or esketamine is 
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also between 40 and 240 minutes after administration, similar to IV infusions 
(Canuso et al., 2018; Daly et al., 2018; Fu et al., 2020; Lapidus et al., 2014). 
The duration of antidepressant benefits is harder to compare across studies. 
Follow-up data from studies of single ketamine infusions have reported 
antidepressant benefits generally lasting between 3 days and 2 weeks after the last 
treatment (Berman et al., 2000; Fava et al., 2020; Murrough, Iosifescu, et al., 2013; 
Zarate et al., 2006). Data from studies that administered a total of 6 IV ketamine 
infusions (2 infusions a week for 3 weeks) found that the mean time to relapse was 
between 2 and 3 weeks after the last infusion, suggesting that repeated infusions 
can slightly increase the duration of antidepressant effects (aan het Rot et al., 2010; 
Cusin et al., 2017; Murrough, Perez, et al., 2013). Wilkinson et al. (2018) reported 
results on 14 patients who received a mean of 25.1 ketamine infusions over an 
average of 75.7 weeks. Half of these patients reported that the antidepressant 
effects of ketamine infusions fade after 3 weeks from the last treatment (Wilkinson 
et al., 2018). The anti-suicidal effects of a single IV ketamine might be longer-lasting 
than its anti-depressant effects, considering that two studies found that anti-SI 
benefits were maintained 4 to 6 weeks after treatment (Grunebaum et al., 2018; Hu 
et al., 2016).  
 For intranasal esketamine, results from clinical trials showed that 
antidepressant effects of ketamine in conjunction with an oral AD were sustained 
for the majority of patients during the 2-month follow-up period. (Daly et al., 2018; 
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Fu et al., 2020). In a phase 3 clinical trial, results indicated that continued 
esketamine treatment significantly reduced relapse rate compared with placebo: 
70% decreased risk in patients with stable response and 50% decreased risk in 
patients in stable remission. In addition, esketamine significantly delayed the onset 
of relapse compared with placebo (Daly et al., 2019). One study investigating long-
term intranasal esketamine treatment found that antidepressant benefits were 
maintained by the majority of patients for the 1-year treatment period (Wajs et al., 
2020). 
 
Safety, Side Effects, Abuse, and Dependence 
Ketamine has been used in clinical settings as an anesthetic for the past 50 
years. The drug is well known for its excellent safety profile because it does not 
cause respiratory depression like many other anesthetics. Perry et al. (2007) 
reviewed the safety of subanesthetic doses of ketamine from 16 studies conducted 
on healthy subjects. From a pool of 833 ketamine IV infusions, no serious adverse 
events were reported, and only 10 infusions were terminated because of side effects 
(Perry et al., 2007). Wan et al. (2014) assessed the safety of IV ketamine as an 
antidepressant from three studies on patients with depression. Based on 205 total 
infusions administered to 97 patients, only 4 were discontinued as a result of an 
adverse event. Other nonserious side effects peaked at 120 minutes and resolved at 
240 minutes postinfusion (Wan et al., 2014). 
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Ketamine is an anesthetic that can cause psychotic side effects. To measure 
psychotic symptoms, researchers use the 4-item positive subscale of The Brief 
Psychiatric Rating Scale (BPRS+) which measures conceptual disorganization, 
hallucinations, suspiciousness, and unusual thought content (Wan et al., 2014). 
Infusions of IV ketamine in subanesthetic doses have been associated with an 
increase in BPRS+ scores, corresponding to an increase in psychotic symptoms. 
BPRS+ scores tend to peak at 40 minutes after ketamine or esketamine infusions, 
and they tend to resolve within 110 to 240 minutes (aan het Rot et al., 2010; 
Berman et al., 2000; Murrough et al., 2015; Murrough, Iosifescu, et al., 2013; 
Murrough, Perez, et al., 2013; Singh et al., 2016; Wan et al., 2014; Zarate et al., 2006). 
For intranasal administrations, one study administering intranasal ketamine 
(Lapidus et al., 2014) and one study administering intranasal esketamine (Wajs et 
al., 2020) reported a small transient increase in BPRS+ scores. In contrast, three 
intranasal esketamine studies measuring psychotic symptoms found no increase in 
BPRS+ scores after intranasal esketamine treatment (Daly et al., 2018; Fedgchin et 
al., 2019; Popova et al., 2019). Results from these studies suggest that intranasal 
administration may have fewer psychotic side effects compared with IV ketamine or 
esketamine administration, although more research on this topic is needed. 
Because ketamine is a dissociative anesthetic, it can also have dissociative 
side effects. Dissociative symptoms are measured using the Clinician-Administered 
Dissociative States Scale (CADSS), in which higher scores correspond to more 
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dissociative symptoms. These symptoms include memory loss, depersonalization, 
derealization, and identity confusion (Bremner et al., 1998). For IV ketamine or 
esketamine infusions, studies have found CADSS scores that peak at 40 minutes 
postinfusion and return to baseline within 80 to 240 minutes (aan het Rot et al., 
2010; Cusin et al., 2017; Fava et al., 2020; Ibrahim et al., 2011; Murrough et al., 
2015; Murrough, Iosifescu, et al., 2013; Murrough, Perez, et al., 2013; Singh et al., 
2016; Wan et al., 2014; Wilkinson et al., 2018). Intranasal esketamine studies 
reported an identical pattern with peak CADSS scores measured at 40 minutes after 
dosing and a return to baseline measured at 1.5 to 24 hours postinfusion (Canuso et 
al., 2018; Daly et al., 2018, 2019; Fedgchin et al., 2019; Popova et al., 2019; Wajs et 
al., 2020). 
Another common side effect associated with ketamine or esketamine is 
hemodynamic changes. Hemodynamic changes occur in a majority of patients after 
IV ketamine treatments. Most cases are transient elevations in blood pressure or 
heart rate that do not require medical intervention or the cessation of treatment 
(aan het Rot et al., 2010; Cusin et al., 2017; Fava et al., 2020; Murrough, Iosifescu, et 
al., 2013; Murrough, Perez, et al., 2013; Zarate et al., 2006). Cusin et al. (2017) found 
that all patients experienced at least a 10-mmHg increase in systolic blood pressure 
during IV ketamine infusions. Murrough, Perez, et al. (2013) reported that 33% of 
patients in their IV ketamine study experienced elevated blood pressure or heart 
rate at least once during the study. However, only 1 patient required termination of 
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treatment as a result of not responding sufficiently to antihypertensive medication 
administration (Murrough, Perez, et al., 2013). Wilkinson et al. (2018) found that 6 
out of 54 patients experienced significantly high blood pressure after IV ketamine 
infusions, and only 1 out of 518 infusions needed to be stopped because of 
hypertension. In their analysis of IV ketamine clinical trials, Wan et al. (2014) found 
that an increase in blood pressure was a common side effect in which 29.8% had a 
significant increase and 14.3% needed medication intervention. For intranasal 
esketamine, a similar trend is present in which the increase in blood pressure peaks 
at about 40 minutes after infusion and resolves within 1.5 to 2 hours postinfusion 
(Canuso et al., 2018; Daly et al., 2018, 2019; Fedgchin et al., 2019; Popova et al., 
2019; Wajs et al., 2020). 
A major concern for the use of ketamine as an antidepressant is its effects on 
cognitive function. Frequent ketamine abuse has been studied in chronic abusers 
and has been associated with a decline in cognitive function, especially memory, and 
an increase in delusional and schizotypal symptoms. This finding is expected 
because the glutamatergic system is known to be essential in memory encoding 
(Morgan et al., 2010). However, the abused doses of ketamine tend to be greater 
than 3 mg/kg, considerably higher than the common 0.5 mg/kg used for 
antidepressant therapies (Hashimoto, 2019). Wilkinson et al. (2018) performed 
regular cognitive testing on patients receiving repeated IV ketamine infusions and 
found no correlation between the number of infusions and changes in cognition. 
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During their study on continuous intranasal esketamine administrations, Wajs et al. 
(2020) reported that all patients performed the same or slightly better on cognitive 
tests through 44 weeks of treatment plus follow-up and that there was no evidence 
of cognitive decline in any patient. Although other studies in this review did not 
include cognitive testing, they also did not mention any cognitive deficits associated 
with ketamine or esketamine administration in doses used for antidepressant 
therapy. Cognitive decline is a serious and potentially life-altering side effect, and 
research should be continued in this area, especially with higher doses or more 
frequent treatments. However, there is no evidence in the current literature that 
either ketamine or esketamine used as antidepressants can cause cognitive decline.  
Ketamine and esketamine are Schedule III controlled substances defined as 
moderate to low risk for physical and psychological dependence by the U.S. Drug 
Enforcement Administration (n.d.). Because of the potential for abuse with 
ketamine, there is concern from the medical community about its repeated use as an 
antidepressant, and the FDA recommends close monitoring of all patients for misuse 
or drug-seeking behavior (Janssen Pharmeceuticals, 2020). Ketamine abuse has 
recently become more popular globally following the ecstasy epidemic. Similar to a 
party drug, ketamine is snorted in powder form by the majority of abusers 
(Hashimoto et al., 2020). Four studies assessed withdrawal symptoms after 
intranasal esketamine treatment using the 20-item Physician Withdrawal Checklist 
and found no evidence indicating a withdrawal syndrome (Daly et al., 2019; 
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Fedgchin et al., 2019; Popova et al., 2019; Wajs et al., 2020). Literature reviews on 
both healthy subjects and MDD patients found no drug dependence or drug-seeking 
behavior after subanesthetic doses of ketamine (Perry et al., 2007; Wan et al., 2014). 
In addition, no study included in this review has made any reports of increased drug 
seeking or abuse of ketamine or any other nonprescription drug after 
antidepressant treatment with ketamine or esketamine. Although concerns remain 
because ketamine is a well-known drug of abuse, evidence suggests that 
antidepressant treatments do not lead to the abuse of this drug. 
The most serious side effect documented with ketamine treatments is 
treatment-emergent suicidal ideation. Fedgchin et al. (2019) found that after 
intranasal esketamine administration, 10% of participants in the 56-mg group, 7% 
in the 84-mg group, and 11% in the placebo group experienced new SI. Similarly, 
Wajs et al. (2020) reported that 14.5% of participants experienced new SI after 
intranasal esketamine treatment. However, both of these studies initiated a new 
oral AD treatment concurrently with esketamine, and it is difficult to differentiate 
the effects of ketamine from the increase in SI observed in the first two weeks of 
oral AD treatment (Rush et al., 2006). Although ketamine has robust anti-SI effects, 
the potential for the emergence or worsening of SI is a serious medical emergency 





 There is ample evidence supporting the efficacy of both ketamine and 
esketamine as antidepressants. Studies of IV ketamine infusions in subanesthetic 
doses on treatment-resistant depression patients report a response rate between 
40% and 70% (Berman et al., 2000; Cusin et al., 2017; Murrough, Iosifescu, et al., 
2013; Murrough, Perez, et al., 2013; Wilkinson et al., 2018; Zarate et al., 2006), with 
an onset of benefits appearing between 40 and 240 minutes after treatment (aan het 
Rot et al., 2010; Berman et al., 2000; DiazGranados et al., 2010; Ibrahim et al., 2011; 
Machado-Vieira et al., 2009; Murrough, Perez, et al., 2013; Zarate et al., 2006). The 
antidepressant actions last for 1 to 3 weeks after the last infusion (aan het Rot et al., 
2010; Berman et al., 2000; Murrough, Perez, et al., 2013; Zarate et al., 2006) and can 
be sustained in the long term with repeated infusions (Wilkinson et al., 2017). In 
addition, oral ADs used concurrently with ketamine infusions are associated with a 
higher response rate of 88.9% and longer-lasting antidepressant actions in TRD 
patients (Hu et al., 2016). The use of IV ketamine infusions is also associated with 
anti-SI effects in both treatment-resistant and nontreatment-resistant MDD patients. 
Results from studies on patients with suicidal ideation have an overall remission 
rate between 50% and 62% within the first 24 hours after administration 




The response rates from intranasal esketamine studies are similarly between 
36% and 76.5% in TRD when used in conjunction with a newly initiated oral AD 
(Fedgchin et al., 2019; Popova et al., 2019; Wajs et al., 2020) The onset of action is 
40 to 240 minutes after the first dose (Canuso et al., 2018; Daly et al., 2018; Fu et al., 
2020; Lapidus et al., 2014). The antidepressant benefits of intranasal esketamine 
appear to be sustained through a 2-month follow-up period in two clinical trials 
(Daly et al., 2018; Fu et al., 2020). Comparable to IV ketamine infusions, repeated 
intranasal esketamine administrations prevent and delay relapse (Daly et al., 2019). 
Intranasal esketamine also has anti-SI effects like ketamine infusions. For MDD 
patients with SI, 40% to 54% of them achieve remission within 24 hours of 
intranasal esketamine treatment in conjunction with an oral antidepressant (Canuso 
et al., 2018; Fu et al., 2020). 
Based on these efficacy results, both IV ketamine infusions and intranasal 
esketamine administrations are more effective than oral ADs in TRD patients, and 
both treatments have a faster onset of therapeutic benefits. In comparison, the 
STAR*D study reported a response rate of 16.4% (≥50% decrease in QIDS-SR 
scores) in treatment-resistant patients (2 or more failed AD trials) with a mean of 
6.4 weeks until response is achieved (Rush et al., 2006). In terms of efficacy and 
onset of benefits, ketamine and esketamine treatments are similar to ECT 
treatments that show rapid antidepressant benefits after the first session with 
response rates of about 50%-60% (Kennedy et al., 2009).  
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 Ketamine has an excellent safety profile and tolerability when used in 
subanesthetic doses for antidepressant treatment. Ketamine does not cause any 
respiratory depression which needs monitoring like other analgesics. Unlike ECT 
treatments, there has been no evidence of cognitive decline associated with 
ketamine used in doses for antidepressant effects (Wajs et al., 2020; Wilkinson et al., 
2017). Ketamine has also proved to be safe from an abuse standpoint. Studies of 
both intranasal and IV administrations have found that antidepressant treatments 
with ketamine do not lead to any ketamine dependence or abuse of ketamine (Daly 
et al., 2019; Fedgchin et al., 2019; Perry et al., 2007; Popova et al., 2019; Wajs et al., 
2020; Wan et al., 2014).  
 Despite the excellent safety profile, ketamine has short-term side effects, 
including hemodynamic changes and psychotic or dissociative symptoms, that limit 
its use to supervised clinical settings. These changes are usually mild and transient 
and do not necessitate medical intervention. Because IV infusions by their nature 
require the administration of ketamine by a healthcare provider, it is easy to ensure 
their safety and to monitor short-term side effects. On the other hand, intranasal 
ketamine and esketamine are self-administered in clinical settings. Therefore, 
intranasal formulations could potentially be prescribed to patients who could 
administer them at home like oral ADs. Further research is needed to determine if 
esketamine can be safely and effectively used by patients at home. 
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 In conclusion, both ketamine and esketamine administered by IV infusions or 
intranasally have similarly strong antidepressant effects, especially when used in 
conjunction with oral ADs. Both formulations also have rapid and robust anti-SI 
effects which can provide relief for MDD patients in emergency settings regardless 
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